MedTrace Logo

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02831387 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2018-10-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.

Conditions

Interventions

DRUG

P-321 Ophthalmic Solution

P-321 Ophthalmic Solution 0.017%

DRUG

P-321 Ophthalmic Solution placebo

Placebo to match P-321 Ophthalmic Solution

Sponsors & Collaborators

  • Parion Sciences

    lead INDUSTRY

Principal Investigators

  • Jose Boyer · Parion Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-06-30
Completion
2017-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02831387 on ClinicalTrials.gov